AIDS Research and Treatment (Jan 2015)

Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria

  • Sandra Omozehio Iwuala,
  • Olufunmilayo A. Lesi,
  • Olufemi Adetola Fasanmade,
  • Anas A. Sabir,
  • Michael Adeyemi Olamoyegun,
  • Charles C. Okany

DOI
https://doi.org/10.1155/2015/402638
Journal volume & issue
Vol. 2015

Abstract

Read online

Background. Although the association between lipoatrophy and highly active antiretroviral therapy (HAART) is well known, other nondrug factors may be associated with lipoatrophy in people living with HIV/AIDS (PLWHA). There are no reports of lipoatrophy from Nigeria, a country with the second largest number of PLWHA. We aimed to determine the prevalence, characteristics, and factors associated with lipoatrophy in a cohort of patients attending the HIV clinic in Lagos University Teaching Hospital, Nigeria. Methods. Two hundred and eighty-eight patients with HIV infection were recruited for the study. The study protocol involved administration of a questionnaire, targeted physical examination (including anthropometric indices and skin fold thickness), and bioelectrical impedance analysis measurements. Lipoatrophy was defined clinically. Results. Lipoatrophy was present in 75 (26.0%) persons. It was associated with lower body circumferences, skin fold thicknesses, and lower % body fat with preservation of skeletal muscle mass (all P<0.05). Male gender and HAART use were the factors associated with lipoatrophy on multivariate analysis (P<0.05). Conclusion. Lipoatrophy is frequently encountered in patients with HIV infection in Nigeria, with HAART use conferring an added factor in its development. There is need for more physician and patient awareness of this condition.